A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.
Advanced Renal Cell Carcinoma
DRUG: AMG 102 at 10 mg/kg|DRUG: AMG 102 at 20 mg/kg
To assess the objective response rate in subjects with advanced renal cell carcinoma receiving AMG 102 treatment, 9 weeks from first dose of AMG 102
To estimate the overall survival and progression free survival rates in this population, 8 week intervals|To assess the duration of response and time to response in this population, treatment period|To assess the pharmacokinetics of AMG 102 in subjects with advanced renal cell carcinoma, Weeks 1, 5, and 9|To assess the safety profile of AMG 102 in subjects with advanced renal cell carcinoma, entire study
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.